Plain-English translation of NCT06074692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining three treatments—a medication called a PARP inhibitor (which blocks cancer cells' ability to repair DNA damage), an immunotherapy drug (which helps your immune system fight cancer), and a type of focused radiation called stereotactic body radiotherapy—can help patients with advanced sarcoma (a cancer of bone or soft tissue) that has spread or cannot be fully removed by surgery. Sarcomas that have come back or spread are hard to treat with standard therapies, and this combination aims to tackle the cancer in a new way.
Most patients with advanced or recurring sarcoma have very poor survival odds with current treatments. Research suggests that some sarcomas have a 'BRCA-like' genetic pattern that makes them sensitive to the medication being tested, and that this medication might also wake up the immune system to fight the cancer more effectively when combined with other treatments.
You likely qualify if…
You likely don't qualify if…
You would take a PARP inhibitor medication by mouth, receive an immunotherapy drug (likely by infusion), and undergo several sessions of focused radiation therapy aimed at your tumor sites. The trial includes three separate groups depending on your type of sarcoma (bone, soft tissue, or a specific subtype), and treatment would continue as long as the cancer is responding and you are tolerating the medications well. You would have regular clinic visits for check-ups, blood work, and scans to monitor how the cancer is responding.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
China